Welcome to our dedicated page for Olink Holding AB (publ) American Depositary Shares news (Ticker: OLK), a resource for investors and traders seeking the latest updates and insights on Olink Holding AB (publ) American Depositary Shares stock.
Olink Holding AB (publ) (Nasdaq: OLK) is a pioneering company in the field of proteomics, dedicated to accelerating scientific discoveries through its innovative Proximity Extension Assay (PEA) technology. Since its founding in 2016, Olink has been at the forefront of proteomics research, providing products and services designed to enhance the understanding of real-time human biology across multiple disease areas. The company’s platform is utilized by major biopharmaceutical firms, clinical institutions, and academic researchers globally.
Olink’s proprietary PEA technology is a versatile tool that enables researchers to conduct studies spanning from initial discovery to clinical trials and even diagnostic applications. This technology leverages existing lab infrastructure and installed instrumentation, making it a highly efficient and scalable solution.
Olink operates through two main segments: Kit and Services. In the Kit segment, the company provides reagents and consumables that researchers can use in their own laboratories. The Services segment offers access to Olink’s technology through its own labs, delivering high-quality data and insights to clients worldwide.
The company is headquartered in Uppsala, Sweden, and has a significant presence in Europe, North America, and Asia. Key revenue is generated from the United States, followed by Sweden, China, EMEA (excluding Sweden), Japan, and other regions. This geographical diversity emphasizes Olink’s global impact and reach.
Olink has recently garnered attention through several strategic initiatives and developments. Notably, on March 20, 2024, Thermo Fisher Scientific received clearance from the Swedish Inspectorate of Strategic Products for a proposed transaction with Olink, expected to be completed by mid-2024. This collaboration is anticipated to further strengthen Olink's capabilities and market presence.
Investor Contacts:
Jan Medina, CFA
VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157
Email: jan.medina@olink.com
Media Contacts:
Michael B. Gonzales, PhD
VP Global Marketing
Mobile: +1 415 308 6467
Email: michael.gonzales@olink.com
Olink Holding AB (Nasdaq: OLK) awarded the 2022 Novelties in Biomarkers prize to Maria Martin-Grau from the University of Valencia at the Biomarkers of the Future conference in Paris. This annual award, established in 2019, aims to promote young researchers in biomarker discovery. The theme for this year attracted over 30 submissions across various medical fields. The conference emphasized the importance of proteomics and the necessity for industry and academia to support young talents in expanding the field. Olink's initiative addresses the existing skills gap in proteomics.
Olink Holding AB (Nasdaq: OLK) has launched the Olink® Flex, a customizable product that allows users to select up to 21 human proteins for analysis using absolute quantification. The Olink® Flex offers significant advantages such as high specificity, sensitivity, and a broad dynamic range, while also enabling efficient workflows with minimal hands-on time. Customers can choose assays from over 200 biomarkers related to various diseases, facilitating targeted research in immunology, oncology, and more. This innovative product enhances Olink's portfolio and aims to meet diverse protein biomarker research needs.
Olink Holding AB (Nasdaq: OLK) reported third-quarter 2022 revenues of $31.8 million, a 59% increase from the prior year. The company's Explore segment contributed $21.7 million or 68% of total revenue, while kits revenue surged 265% year-over-year to $13.4 million. Olink anticipates full-year 2022 revenue between $138 million and $142 million, reflecting strong growth rates. Adjusted EBITDA improved to ($1.7 million) versus ($7.5 million) in Q3 2021, demonstrating recovery. However, foreign currency headwinds impacted expectations.
Olink (Nasdaq: OLK) announced a significant milestone, surpassing 1,000 peer-reviewed publications utilizing its Proximity Extension Assay (PEA) technology. This achievement highlights the rapid adoption of Olink's protein biomarker solutions in scientific research, with over 230 articles published in 2022 alone. The technology is applicable to diverse research areas, including cardiovascular, metabolic, neurological, and immunological diseases, as well as COVID-19. Olink's scalable technology supports studies ranging from small sample analyses to large international projects, emphasizing its transformative role in proteomics and precision medicine.
Olink Holding AB (Nasdaq: OLK) announced participation in two upcoming investor events. The Olink Investor Day 2022 is scheduled for November 14 at 11:00 am ET, followed by the Canaccord Genuity MedTech Forum on November 17 at 2:00 pm ET. A live and archived webcast of the Investor Day will be accessible on Olink's website. Founded in 2016 and headquartered in Uppsala, Sweden, Olink focuses on advancing proteomics to enable scientific discoveries and improve patient outcomes.
On October 24, 2022, Olink Holding AB (Nasdaq: OLK) launched Olink® Insight, a new online platform designed to enhance proteomics data analysis. This platform features tools like Pathway Explorer, Annotation, and Normal Ranges, aimed at simplifying user experiences with protein studies. Olink's commitment to innovation is reflected in its collaboration with the scientific community to provide high-quality, actionable data. The platform will initially focus on cancer in its upcoming Disease Atlas, expanding to other diseases in the future.
Olink Holding AB (Nasdaq: OLK) will announce its financial results for Q3 2022 on November 10, 2022, before the market opens. A conference call with company management will follow at 8:00 am ET, providing insights into the financial performance and strategic direction of the company. Interested investors can register online for the call, and a live webcast will also be available on Olink's website. The webcast will be archived for 90 days.
Personalis, Inc. (NASDAQ: PSNL) has partnered with Duke University and Olink Proteomics AB to research the effects of immunotherapy on advanced gastroesophageal cancer. The collaboration aims to identify composite biomarkers to enhance therapeutic decision-making. Gastroesophageal cancer is prevalent, with nearly 50% of patients facing advanced stages at diagnosis. Key goals include understanding responses to pembrolizumab, an approved immunotherapy, and developing strategies to optimize treatment effectiveness. The study will leverage Personalis' cutting-edge technology for comprehensive tumor profiling.
Olink Holding AB (Nasdaq: OLK) has partnered with Discovery Life Sciences to create the largest commercial platform for Olink's technology in the Americas, enhancing proteomics research capabilities. This collaboration aims to facilitate the discovery and validation of protein biomarkers, bridging the gap between genomics and phenotypes. Olink's PEA technology will complement Discovery's existing services, including genomic and tissue biomarkers, improving drug development processes. This strategic alliance is positioned to expand Olink's market reach and support precision medicine initiatives.
On September 20, 2022, Discovery Life Sciences announced a major collaboration with Olink Holding AB to install the largest commercial platform of Olink's PEA technology in the Americas. This partnership aims to enhance biomarker discovery and validation services, positioning Discovery as a leading global certified service provider. The Olink PEA technology supports high-specificity proteomics, offering dual readout options like next-generation sequencing and qPCR. This installation significantly expands Discovery's multi-omic capabilities, furthering their commitment to innovation in precision medicine.
FAQ
What is the current stock price of Olink Holding AB (publ) American Depositary Shares (OLK)?
What is the market cap of Olink Holding AB (publ) American Depositary Shares (OLK)?
What does Olink Holding AB specialize in?
What are the main segments of Olink's operations?
Where is Olink Holding AB headquartered?
Which markets generate the most revenue for Olink?
What is Olink's Proximity Extension Assay (PEA) technology?
Who are the key contacts for investors and media at Olink?
What recent strategic developments has Olink been involved in?
When was Olink Holding AB founded?
What industries benefit from Olink's services?
How can researchers use Olink's products?
